NO992400L - Nye substituerte pyrazolderivater - Google Patents
Nye substituerte pyrazolderivaterInfo
- Publication number
- NO992400L NO992400L NO992400A NO992400A NO992400L NO 992400 L NO992400 L NO 992400L NO 992400 A NO992400 A NO 992400A NO 992400 A NO992400 A NO 992400A NO 992400 L NO992400 L NO 992400L
- Authority
- NO
- Norway
- Prior art keywords
- pyrazole derivatives
- substituted pyrazole
- new substituted
- medicaments
- new
- Prior art date
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical class C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19649460A DE19649460A1 (de) | 1996-11-26 | 1996-11-26 | Neue substituierte Pyrazolderivate |
| PCT/EP1997/006366 WO1998023619A1 (fr) | 1996-11-26 | 1997-11-14 | Nouveaux derives de pyrazole substitues pour le traitement de maladies cardio-vasculaires |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO992400D0 NO992400D0 (no) | 1999-05-19 |
| NO992400L true NO992400L (no) | 1999-05-19 |
Family
ID=7813100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO992400A NO992400L (no) | 1996-11-26 | 1999-05-19 | Nye substituerte pyrazolderivater |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0944631B1 (fr) |
| JP (2) | JP4422800B2 (fr) |
| CN (1) | CN1122032C (fr) |
| AR (1) | AR010310A1 (fr) |
| AT (1) | ATE259812T1 (fr) |
| AU (1) | AU729642B2 (fr) |
| BR (1) | BR9714363A (fr) |
| CA (1) | CA2272584C (fr) |
| CZ (1) | CZ185099A3 (fr) |
| DE (2) | DE19649460A1 (fr) |
| DK (1) | DK0944631T3 (fr) |
| EE (1) | EE9900211A (fr) |
| ES (1) | ES2214646T3 (fr) |
| HU (1) | HUP0000562A3 (fr) |
| ID (1) | ID21881A (fr) |
| IL (1) | IL129998A0 (fr) |
| MX (1) | MXPA99004826A (fr) |
| NO (1) | NO992400L (fr) |
| NZ (1) | NZ335890A (fr) |
| PT (1) | PT944631E (fr) |
| SK (1) | SK67699A3 (fr) |
| TR (1) | TR199901172T2 (fr) |
| TW (1) | TW403746B (fr) |
| WO (1) | WO1998023619A1 (fr) |
| ZA (1) | ZA9710573B (fr) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE19827679A1 (de) * | 1998-06-22 | 1999-12-23 | Dresden Arzneimittel | Adenosinrezeptoraffine, antikonvulsiv und antiallergisch/antiasthmatisch wirkende Pyrazolo[3,4-d]pyrimidine und Verfahren zu deren Herstellung |
| DE19834044A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834045A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| DE19920352A1 (de) * | 1999-05-04 | 2000-11-09 | Bayer Ag | Substituiertes Pyrazolderivat |
| DE19943635A1 (de) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10021069A1 (de) * | 2000-04-28 | 2001-10-31 | Bayer Ag | Substituiertes Pyrazolderivat |
| DE10057754A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Sulfonamid-substituierte Pyrazolopyridinderivate |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
| EP1339716B1 (fr) | 2000-11-22 | 2004-11-03 | Bayer HealthCare AG | derives de pyrazolopyridine substitues par un lactame |
| DE10109861A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate |
| DE10109858A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige halogensubstituierte Aminodicarbonsäurederivate |
| DE10110749A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10122894A1 (de) | 2001-05-11 | 2002-11-14 | Bayer Ag | Neue Sulfonat-substituierte Pyrazolopyridinderivate |
| DE10132416A1 (de) * | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE10232572A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | Neue 2,5-disubstituierte Pyrimidinderivate |
| DE10244810A1 (de) * | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
| US7226941B2 (en) * | 2003-06-30 | 2007-06-05 | Hif Bio, Inc. | Compound for treating angiogenesis |
| DE102005050377A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
| DE102005050497A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Difluorphenol-Derivate und ihre Verwendung |
| DE102005050498A1 (de) | 2005-10-21 | 2007-06-06 | Bayer Healthcare Aktiengesellschaft | Cyclopropylessigsäure-Derivate und ihre Verwendung |
| DE102005050376A1 (de) | 2005-10-21 | 2007-05-31 | Bayer Healthcare Ag | Dicarbonsäure-Derivate und ihre Verwendung |
| DE102005050375A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Tetrazol-Derivate und ihre Verwendung |
| DE102006020327A1 (de) * | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
| DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| DE102007015034A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Lactam-substituierte Dicarbonsäuren und ihre Verwendung |
| DE102007015035A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituierte Dibenzoesäure-Derivate und ihre Verwendung |
| DE102007026392A1 (de) | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
| DE102007028406A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028320A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028407A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028319A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| CA2722772C (fr) | 2008-04-28 | 2020-12-22 | Janssen Pharmaceutica N.V. | Benzoimidazoles comme inhibiteurs de la prolyl hydroxylase |
| EP2138178A1 (fr) | 2008-06-28 | 2009-12-30 | Bayer Schering Pharma Aktiengesellschaft | Oxazolidinones pour le traitement de maladie pulmonaire obstructive chronique (MPOC) et/ou de l'asthme |
| DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
| DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
| UY33041A (es) | 2009-11-27 | 2011-06-30 | Bayer Schering Pharma Aktienegesellschaft | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico |
| GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| CN107021951B (zh) | 2010-06-30 | 2020-10-20 | 赛克里翁治疗有限公司 | sGC刺激物 |
| ES2572803T3 (es) | 2010-11-09 | 2016-06-02 | Ironwood Pharmaceuticals, Inc. | Estimuladores de GCs |
| EP2699578B1 (fr) * | 2011-04-21 | 2016-04-20 | Bayer Intellectual Property GmbH | Pyrazolopyridines substituées par un fluoro-alkyle et leur utilisation |
| CA2847193A1 (fr) | 2011-09-14 | 2013-03-21 | Proximagen Limited | Nouveaux composes inhibiteurs enzymatiques |
| EP3112363A1 (fr) | 2011-12-27 | 2017-01-04 | Ironwood Pharmaceuticals, Inc. | Dérivés de pyrimidine 2-[1-[(2-fluorophényl)méthyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl] et composés similaires en tant que stimulateurs de la cyclase soluble du guanylate (csg) pour le traitement de l'hypertension pulmonaire |
| CA2872926C (fr) | 2012-05-10 | 2022-07-05 | Bayer Pharma Aktiengesellschaft | Anticorps capables de lier au facteur de coagulation xi et/ou a sa forme activee, le facteur xia, et utilisations de ceux-ci |
| WO2015106268A1 (fr) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | Utilisation de stimulateurs de la sgc pour le traitement de troubles neuromusculaires |
| AU2016258847A1 (en) | 2015-05-06 | 2017-11-16 | Bayer Pharma Aktiengesellschaft | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of Digital Ulcers (DU) concomitant to Systemic Sclerosis (SSc) |
| WO2017013010A1 (fr) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulateurs et/ou activateurs de la guanylate-cyclase soluble (sgc) en association avec un inhibiteur de l'endopeptidase neutre (inhibiteur nep) et/ou des antagonistes d'une angiotensine ii et leur utilisation |
| CN108463224A (zh) | 2015-12-14 | 2018-08-28 | 铁木医药有限公司 | sGC刺激剂用于胃肠功能障碍治疗的应用 |
| WO2017121700A1 (fr) * | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Dérivés de 1h-pyrazolo[3,4-b]pyridine 1,3-disubstitués et leur utilisation en tant que stimulateurs de la guanylacte cyclase soluble |
| EP3525779B1 (fr) | 2016-10-11 | 2024-06-05 | Bayer Pharma Aktiengesellschaft | Combinaison contenant le stimulateur sgc vericugat et l'antagoniste des récepteurs minéralcorticoïdes finerenone |
| EP3525778A1 (fr) | 2016-10-11 | 2019-08-21 | Bayer Pharma Aktiengesellschaft | Combinaison contenant des activateurs gcs et des antagonistes du récepteur des minéralocorticoïdes |
| EP3554488A2 (fr) | 2016-12-13 | 2019-10-23 | Cyclerion Therapeutics, Inc. | Utilisation de stimulateurs de sgc pour le traitement de la motilité sophagienne |
| CN108727340B (zh) | 2017-04-11 | 2020-12-29 | 广东东阳光药业有限公司 | 氟取代的吲唑类化合物及其用途 |
| JOP20200287A1 (ar) | 2018-05-15 | 2020-11-09 | Bayer Ag | بنزاميدات مستبدلة بـ 3،1- ثيازول-2- يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية |
| US12220414B2 (en) | 2018-07-11 | 2025-02-11 | Tisento Therapeutics Inc. | Use of sGC stimulators for the treatment of mitochondrial disorders |
| WO2020164008A1 (fr) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Procédé de préparation de microparticules poreuses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0615542B2 (ja) * | 1986-07-22 | 1994-03-02 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
| US4994482A (en) * | 1989-07-31 | 1991-02-19 | Bristol-Myers Squibb Company | Arylpyrazol derivatives as anti-platelet agents, compositions and use |
| EP0641564A4 (fr) * | 1992-05-21 | 1995-05-03 | Yoshitomi Pharmaceutical | Compose de pyrazole condense optiquement actif, pour le traitement de la thrombocytopenie et de l'erythropenie. |
| JP2928079B2 (ja) * | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| CN1039536C (zh) * | 1994-02-28 | 1998-08-19 | 永信药品工业股份有限公司 | 1,3取代缩合吡唑类化合物及其应用和制备方法 |
-
1996
- 1996-11-26 DE DE19649460A patent/DE19649460A1/de not_active Withdrawn
-
1997
- 1997-11-14 SK SK676-99A patent/SK67699A3/sk unknown
- 1997-11-14 MX MXPA99004826A patent/MXPA99004826A/es not_active IP Right Cessation
- 1997-11-14 CN CN97180065A patent/CN1122032C/zh not_active Expired - Fee Related
- 1997-11-14 CA CA002272584A patent/CA2272584C/fr not_active Expired - Fee Related
- 1997-11-14 AT AT97951204T patent/ATE259812T1/de active
- 1997-11-14 CZ CZ991850A patent/CZ185099A3/cs unknown
- 1997-11-14 JP JP52421898A patent/JP4422800B2/ja not_active Expired - Fee Related
- 1997-11-14 PT PT97951204T patent/PT944631E/pt unknown
- 1997-11-14 BR BR9714363A patent/BR9714363A/pt active Search and Examination
- 1997-11-14 WO PCT/EP1997/006366 patent/WO1998023619A1/fr not_active Ceased
- 1997-11-14 DK DK97951204T patent/DK0944631T3/da active
- 1997-11-14 DE DE59711321T patent/DE59711321D1/de not_active Expired - Lifetime
- 1997-11-14 EP EP97951204A patent/EP0944631B1/fr not_active Expired - Lifetime
- 1997-11-14 IL IL12999897A patent/IL129998A0/xx unknown
- 1997-11-14 ID IDW990388A patent/ID21881A/id unknown
- 1997-11-14 HU HU0000562A patent/HUP0000562A3/hu unknown
- 1997-11-14 NZ NZ335890A patent/NZ335890A/en unknown
- 1997-11-14 ES ES97951204T patent/ES2214646T3/es not_active Expired - Lifetime
- 1997-11-14 EE EEP199900211A patent/EE9900211A/xx unknown
- 1997-11-14 TR TR1999/01172T patent/TR199901172T2/xx unknown
- 1997-11-14 AU AU54823/98A patent/AU729642B2/en not_active Ceased
- 1997-11-21 TW TW086117406A patent/TW403746B/zh not_active IP Right Cessation
- 1997-11-25 ZA ZA9710573A patent/ZA9710573B/xx unknown
- 1997-11-26 AR ARP970105563A patent/AR010310A1/es active IP Right Grant
-
1999
- 1999-05-19 NO NO992400A patent/NO992400L/no unknown
-
2009
- 2009-09-11 JP JP2009210476A patent/JP2010013475A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL129998A0 (en) | 2000-02-29 |
| AU729642B2 (en) | 2001-02-08 |
| ID21881A (id) | 1999-08-05 |
| DE59711321D1 (de) | 2004-03-25 |
| EP0944631A1 (fr) | 1999-09-29 |
| JP2001505567A (ja) | 2001-04-24 |
| WO1998023619A1 (fr) | 1998-06-04 |
| TR199901172T2 (xx) | 1999-08-23 |
| MXPA99004826A (es) | 2008-02-19 |
| NO992400D0 (no) | 1999-05-19 |
| DK0944631T3 (da) | 2004-06-07 |
| ZA9710573B (en) | 1998-06-10 |
| HK1023119A1 (en) | 2000-09-01 |
| BR9714363A (pt) | 2000-03-21 |
| CA2272584C (fr) | 2007-10-16 |
| CZ185099A3 (cs) | 1999-08-11 |
| TW403746B (en) | 2000-09-01 |
| DE19649460A1 (de) | 1998-05-28 |
| SK67699A3 (en) | 2000-02-14 |
| ATE259812T1 (de) | 2004-03-15 |
| NZ335890A (en) | 2001-02-23 |
| JP4422800B2 (ja) | 2010-02-24 |
| ES2214646T3 (es) | 2004-09-16 |
| AU5482398A (en) | 1998-06-22 |
| CN1122032C (zh) | 2003-09-24 |
| EE9900211A (et) | 1999-12-15 |
| PT944631E (pt) | 2004-06-30 |
| EP0944631B1 (fr) | 2004-02-18 |
| AR010310A1 (es) | 2000-06-07 |
| HUP0000562A3 (en) | 2001-12-28 |
| JP2010013475A (ja) | 2010-01-21 |
| CN1238773A (zh) | 1999-12-15 |
| CA2272584A1 (fr) | 1998-06-04 |
| HUP0000562A2 (hu) | 2000-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO992400L (no) | Nye substituerte pyrazolderivater | |
| NO991732L (no) | Nye heterocyklylmetylsubstituerte pyrazolderivater | |
| MY133392A (en) | Novel substituted pyrazole derivatives | |
| NO20030374D0 (no) | Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter | |
| NO20075065L (no) | Anvendelse av isoflavonforbindelser til a behandle hjertesykdom | |
| IS4226A (is) | Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum | |
| NO20093464L (no) | Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika | |
| NO20006645D0 (no) | Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme | |
| EA200100958A1 (ru) | Производные 4,5-диарил-3(2h)-фуранона как ингибиторы циклооксигеназы-2 | |
| NO990433L (no) | Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet | |
| RU95111308A (ru) | Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция | |
| NO20050664L (no) | 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer | |
| TR199700956T1 (xx) | Indazolkarboksamidler. | |
| NO995431D0 (no) | Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse | |
| TR200100637T2 (tr) | Yeni doğal ürün türevleri | |
| NO970573D0 (no) | Ylidenforbindelser og deres fremstilling | |
| ATE322244T1 (de) | Verwendung von polyaminosäurederivaten zur behandlung von seborrhoe und verwandten hautstörungen | |
| HK1045987A1 (zh) | 3-氨基-2-苄基-1-苯基-丙烷衍生物 | |
| NO952601L (no) | Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser | |
| NO991589L (no) | Nye 3-,5- og/eller 6-substituerte analoger av swainsonin, fremgangsmÕter for deres fremstilling og deres anvendelse som terapeutiske midler | |
| TR200400907T4 (tr) | Beta D 5-Tiyoksiloz türevleri, bunları hazırlama yöntemi ve bunların terapötik kullanımları | |
| NO20020308D0 (no) | Fremgangsmåte for fremstilling av epothiolon B og derivater, såvel som mellomprodukter for fremgangsmåten | |
| HUP9801925A1 (hu) | Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására | |
| DK1232173T3 (da) | Nye fusidinsyrederivater | |
| CY1111290T1 (el) | Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης |